OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference
September 06 2022 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), today announced it will be
featured as a presenting company at the H.C. Wainwright 24th Annual
Global Investment Conference. The conference is being held as
a hybrid in-person and virtual event on September 12-14, 2022.
The in-person venue for the event is the Lotte
New York Palace Hotel in New York City located at 455 Madison
Avenue. Virtual participation will be staged simultaneously with
over 500 company presentations scheduled as live feed or available
on-demand.
Oliver Schacht, CEO, and Albert Weber, CFO, will
be available for in-person meetings at the conference, and
management will provide an overview of the Company's business
during the company’s presentation.
Those interested can listen to the Company’s
presentation by registering for the conference at the following
link (https://www.hcwevents.com/annualconference).
Over 500 corporate presentations and panels held
at the conference will be available during September 12-14,
2022.Event: H.C. Wainwright 24th Annual Global Investment
Conference (Hybrid Conference)
Date: September 12-14, 2022Presentation Day & Time:
September 12, 2022 at 4:00 PM (ET)Location: In-person in
Kennedy II – 4th Floor at the Lotte New York Palace Hotel, New
York, NY |
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with our subsidiaries, Curetis GmbH and Ares
Genetics GmbH, we are developing and commercializing molecular
microbiology solutions helping to guide clinicians with more rapid
and actionable information about life threatening infections to
improve patient outcomes and decrease the spread of infections
caused by multidrug-resistant microorganisms, or MDROs. OpGen’s
current product portfolio includes Unyvero, Acuitas AMR Gene
Panel, and the ARES Technology Platform including ARESdb, NGS
technology and AI-powered bioinformatics solutions for antibiotic
response prediction including ARESiss, ARESid, and AREScloud, as
well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
Forward-Looking StatementsThis
press release includes statements regarding OpGen’s participation
at the H.C. Wainwright 24th Annual Global Investment Conference.
These statements and other statements regarding OpGen’s future
plans and goals constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934 and are intended to
qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties that are often difficult to
predict, are beyond our control, and which may cause results to
differ materially from expectations. Factors that could cause our
results to differ materially from those described include, but are
not limited to, the success of our commercialization efforts, our
ability to successfully, timely and cost-effectively develop, seek
and obtain regulatory clearance for and commercialize our product
and services offerings, the rate of adoption of our products and
services by hospitals and other healthcare providers, the fact that
we may not effectively use proceeds from recent financings, the
continued realization of expected benefits of our business
combination transaction with Curetis GmbH, the continued impact of
COVID-19 on the Company’s operations, financial results, and
commercialization efforts as well as on capital markets and general
economic conditions, our ability to satisfy debt obligations under
our loan with the European Investment Bank, the effect of the
military action in Russia and Ukraine on our distributors,
collaborators and service providers, our liquidity and working
capital requirements, the effect on our business of existing and
new regulatory requirements, and other economic and competitive
factors. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please review our
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the date of this press
release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment
bank dedicated to providing corporate finance, strategic advisory
and related services to public and private companies across
multiple sectors and regions. H.C. Wainwright & Co. also
provides research and sales and trading services to institutional
investors. According to Sagient Research Systems, H.C. Wainwright’s
team is ranked as the #1 Placement Agent in terms of aggregate CMPO
(confidentially marketed public offering), RD (registered direct
offering) and PIPE (private investment in public equity) executed
cumulatively since 1998.
For more information visit H.C. Wainwright &
Co. on the web at www.hcwco.com
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew
Bretzius FischTank Marketing and PR
matt@fischtankpr.com
OpGen Investor Contact:Alyssa
FactorEdison Groupafactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024